

## 7½<sup>th</sup> RSC / SCI Symposium on GPCRs in Medicinal Chemistry

### The meeting will consist of:

First disclosures of clinical candidates  
Case studies in GPCR drug discovery and development  
New structural biology and drug design  
Allosteric modulation & biased signalling  
Two afternoon sessions on 24<sup>th</sup> and 25<sup>th</sup> February  
Exhibitor opportunities

### Registration

Registration is open.  
£75 RSC or SCI member\*  
£100 Non-member  
£35 RSC or SCI student\*\* member  
£50 Student\*\* non-member

\* Member is paid-up member of the RSC or SCI.

\*\* Student is undergraduate or post-graduate, not post-doc, and does not apply to students in paid employment.

### Exhibitor Opportunities

We are offering two alternative packages to our valued supporters:

- Exhibitor Sponsorship Package, charged at £150
  - Speaker Sponsorship Package, charged at £250 - fully booked
- Full details of both packages may be found on the event website. Both packages exclude any delegate registration.

### Organising Committee


Daniele Andreotti, Evotec  
Adrian Hall (co-chairman), UCB  
Duncan Hay (treasurer), Vertex  
Caroline Low (co-chairman), Google Deepmind  
Nigel Swain, Sosei Heptares

Twitter  
#GPCRs21

### Secretariat Contact

RSC-BMCS secretariat:  
Maggi Churchouse, telephone +44 (0)1359 221004,  
maggi@maggichurchousevents.co.uk

**Website:** <https://www.maggichurchousevents.co.uk/bmcs>  
Also <https://www.rscbmcs.org/events> and [www.soci.org/events](https://www.soci.org/events)



## 7½<sup>th</sup> RSC / SCI symposium on GPCRs in Medicinal Chemistry

Wednesday & Thursday, 24<sup>th</sup> & 25<sup>th</sup> February 2021

### A virtual symposium

Organised by:  
RSC Biological and Medicinal Chemistry Sector and  
SCI Fine Chemicals Group



## Synopsis

The key role of G protein-coupled receptors (GPCRs) in human disease underpins their importance to modern medicine. We are pleased to be holding this 7½<sup>th</sup> interim meeting in the series on GPCR drug discovery, which will combine cutting edge medicinal chemistry with innovative structural biology and novel drug design approaches.

## Programme

### Wednesday, 24<sup>th</sup> February

Session chair: **Adrian Hall**, UCB, BE

13.00 *Opening remarks*

13.05 *The resolution revolution: GPCR structure-based drug design in 20:20 vision (in 2021)*  
**James Errey**, Evotec, UK

13.40 *Automated cartridge-based synthesis: a new Tool for medicinal chemists*  
**Paula Nichols**, Synple Chem, CH

13.45 *Structurally enabled discovery of orally bioavailable macrocyclic antagonists of the Calcitonin Gene-Related Peptide (CGRP) receptor*  
**Andrew Cansfield**, Sosei Heptares, UK

14.20 Refreshment break

Session chair: **Barbara Bertani**, Evotec, IT

14.35 *The Confo Therapeutics technology platform enabling GPCR fragment-based drug discovery*  
**Christel Menet**, Confo Therapeutics, BE

15.10 *Activate Scientific: chemistry services for drug discovery*  
**Mike Crebbin**, Activate Scientific, UK

15.15 *Discovery of brain penetrant vasopressin 1a receptor antagonists*  
**Hasane Ratni**, F Hoffmann-La Roche, CH

15.50 Open discussion

16.15 Close

### Thursday, 25<sup>th</sup> February

Session chair: **Daniele Andreotti**, Evotec, IT

13.00 *Opening remarks*

13.05 *Structure of a  $\beta_1$ -adrenoceptor coupled to either a G protein mimetic or  $\beta$ -arrestin1: implications for biased drug development*  
**Chris Tate**, Laboratory of Molecular Biology, Medical Research Council, UK

13.40 *BLD - accelerating drug discovery*  
**Andrew Fraser**, BLD Pharmatech, DE

13.45 *Receptor mutations meets ligand SAR: a powerful tool to aid computational modelling*  
**Anneli Nordqvist**, AstraZeneca, SE

14.20 Refreshment break

Session chair: **Caroline Low**, Consultant, UK

14.35 *The challenging task of modulating the GABA<sub>B</sub> receptor: an academic perspective*  
**Claudia Mugnaini**, University of Siena, IT

15.10 *Integrated drug discovery for GPCR targets*  
**Steve Hastwell**, BioAscent Discovery, UK

15.15 *BAY 2395840 - a potent and selective hBradykinin B1 receptor antagonist, generated within the Bayer-Evotec Strategic Alliance*  
**Adam Davenport**, Evotec, UK

15.50 *Closing remarks*  
followed by Open discussion

16.15 Close



Supported by:  EUROPEAN FEDERATION FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY

Twitter

#GPCRs21

Website: <https://www.maggichurchousevents.co.uk/bmcs>

Also <https://www.rscbmcs.org/events> and [www.soci.org/events](http://www.soci.org/events)